Literature DB >> 12484802

Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Niklas Zethraeus1, Magnus Johannesson, Bengt Jönsson, Mickael Löthgren, Magnus Tambour.   

Abstract

No consensus has yet been reached on how to analyse uncertainty in economic evaluation studies where individual patient data are available for costs and health effects. This paper summarises the available results regarding the analysis of uncertainty on the cost-effectiveness plane and argues for using the net-benefit approach when analysing uncertainty in cost-effectiveness studies. The net-benefit approach avoids the interpretation and statistical problems related to the incremental cost effectiveness ratio and implies several advantages. First, traditional statistical methods can be used for confidence-interval estimation and hypothesis testing. Second, calculation of the optimal sample size and the power of the study are facilitated allowing the correlation between costs and effects to vary within and between patient groups. Third, the use of a Bayesian approach to cost-effectiveness analysis is facilitated. Fourth, a formal relation between cost-effectiveness acceptability curves and statistical inference is provided. Finally, the net-benefit approach gives the Fieller's limits of the confidence interval for the incremental cost-effectiveness ratio in the cost-effectiveness plane. Based on these advantages the net-benefit approach should strongly be considered when analysing uncertainty in cost-effectiveness analyses.

Entities:  

Mesh:

Year:  2003        PMID: 12484802     DOI: 10.2165/00019053-200321010-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  25 in total

1.  Fieller's method and net health benefits.

Authors:  D F Heitjan
Journal:  Health Econ       Date:  2000-06       Impact factor: 3.046

2.  Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data.

Authors:  A R Willan
Journal:  Control Clin Trials       Date:  2001-06

3.  Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.

Authors:  A R Willan; B J O'Brien
Journal:  Health Econ       Date:  1999-05       Impact factor: 3.046

4.  Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals.

Authors:  K Claxton
Journal:  Health Econ       Date:  1999-05       Impact factor: 3.046

5.  Is it really so bad to be unambiguously inefficient? The role of dominance in stochastic cost-effectiveness analysis.

Authors:  A A Stinnett
Journal:  Med Decis Making       Date:  1999 Jan-Mar       Impact factor: 2.583

6.  Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane.

Authors:  A Briggs; P Fenn
Journal:  Health Econ       Date:  1998-12       Impact factor: 3.046

7.  Adjusting for bias in C/E ratio estimates.

Authors:  A A Stinnett
Journal:  Health Econ       Date:  1996 Sep-Oct       Impact factor: 3.046

8.  Confidence intervals for cost/effectiveness ratios.

Authors:  P Wakker; M P Klaassen
Journal:  Health Econ       Date:  1995 Sep-Oct       Impact factor: 3.046

9.  The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.

Authors:  B Jönsson; J R Cook; T R Pedersen
Journal:  Diabetologia       Date:  1999-11       Impact factor: 10.122

10.  Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.

Authors:  A Gray; M Raikou; A McGuire; P Fenn; R Stevens; C Cull; I Stratton; A Adler; R Holman; R Turner
Journal:  BMJ       Date:  2000-05-20
View more
  33 in total

1.  Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.

Authors:  Helen Dakin; Morris Sherman; Scott Fung; Carrie Fidler; Anthony Bentley
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

2.  Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.

Authors:  Naiyana Praditsitthikorn; Yot Teerawattananon; Sripen Tantivess; Supon Limwattananon; Arthorn Riewpaiboon; Saibua Chichareon; Nantakan Ieumwananonthachai; Viroj Tangcharoensathien
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

3.  Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters.

Authors:  Jeffrey S Hoch; Carolyn S Dewa
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation.

Authors:  Sutat Kantito; Surasak Saokaew; Sukit Yamwong; Prin Vathesatogkit; Wisuit Katekao; Piyamitr Sritara; Nathorn Chaiyakunapruk
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

5.  Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models.

Authors:  Anthony J Hatswell; Ash Bullement; Andrew Briggs; Mike Paulden; Matthew D Stevenson
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

6.  Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia.

Authors:  H Y Chong; Z Mohamed; L L Tan; D B C Wu; F H Shabaruddin; M Dahlui; Y D Apalasamy; S R Snyder; M S Williams; J Hao; L H Cavallari; N Chaiyakunapruk
Journal:  Br J Dermatol       Date:  2017-09-21       Impact factor: 9.302

7.  Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model.

Authors:  A M Schott; C Ganne; D Hans; G Monnier; R Gauchoux; M A Krieg; P D Delmas; P J Meunier; C Colin
Journal:  Osteoporos Int       Date:  2006-10-13       Impact factor: 4.507

8.  Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults.

Authors:  Benjamin D Smith; Jing Jiang; Joe Y Chang; James Welsh; Anna Likhacheva; Thomas A Buchholz; Stephen G Swisher; Shervin M Shirvani
Journal:  J Geriatr Oncol       Date:  2015-06-17       Impact factor: 3.599

9.  Prolonged conservative care versus early surgery in patients with sciatica from lumbar disc herniation: cost utility analysis alongside a randomised controlled trial.

Authors:  Wilbert B van den Hout; Wilco C Peul; Bart W Koes; Ronald Brand; Job Kievit; Ralph T W M Thomeer
Journal:  BMJ       Date:  2008-05-23

10.  Comparison of cost-effectiveness of vitamin D screening with that of universal supplementation in preventing falls in community-dwelling older adults.

Authors:  Richard H Lee; Thomas Weber; Cathleen Colón-Emeric
Journal:  J Am Geriatr Soc       Date:  2013-04-30       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.